Cytoplasmic TDP-43 inclusion bodies are pathogenic hallmarks for TDP-43 proteinopathies consisting of several neurodegenerative diseases. TDP-43 inclusions were found in 95% amyotrophic lateral sclerosis (ALS), 50% frontotemporal lobar dementia (FTLD), and >30-57% Alzheimer’s disease (AD) patients. This technology is a humanized monoclonal antibody specific for the misfolded TDP-43 oligomers. This antibody has development potential for disease treatment and diagnosis.
